Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 4, 2007, Pages 324-333

  Melis, M ^a   Forrer, F ^a   Capello, A ^a   Bijster, M ^a   Bernard, B F ^a   Reubi, J C ^b   Krenning, E P ^a   De Jong, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Radiolabelled peptides; Receptors; Somatostatin receptor 2; Upregulation

Indexed keywords

OCTREOTATE[3 TYROSINE][1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LUTETIUM LU 177]; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTORADIOGRAPHY; CANCER CELL; CONFERENCE PAPER; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOTOPE LABELING; LEWIS RAT; LOW DRUG DOSE; MALE; NONHUMAN; PANCREAS TUMOR; PROTEIN EXPRESSION; RADIATION ABSORPTION; RADIATION DOSE; RADIATION RESPONSE; RAT; RECEPTOR UPREGULATION; TUMOR GROWTH; TUMOR RECURRENCE;

ANIMALS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RATS; RATS, INBRED LEW; RECEPTORS, SOMATOSTATIN; TREATMENT OUTCOME; UP-REGULATION;

EID: 37249024796     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Ducreux M, Ruszniewski P, Chayvialle JA, Blumberg J, Cloarec D, Michel H et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol 2000;95:3276-81.
2. Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002;79:180-7.
3. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ et al. Phase I study of peptide receptor radionuclide therapy with [in-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22.
4. 3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2006;36:147-56.
5. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273-82.
6. de Jong M, Breeman WA, Bakker WH, Kooij PP, Bernard BF, Hofland LJ et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 1998;58:437-41.
7. Esser JP, Krenning EP, Teunissen JJ, Kooij PP, van Gameren AL, Bakker WH et al. Comparison of [(177)Lu-DOTA (0),Tyr (3)]octreotate and [(177)Lu-DOTA (0),Tyr (3)]octreotide: which peptide is preferable for PRRT? Eur J Nucl Med Mol Imaging 2006;33:1346-51.
8. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92:628-33.
9. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467-75.
10. Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46 Suppl 1:83S-91S.
11. 3] octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23:2754-62.
12. 3] octreotate. J Clin Oncol 2004;22:2724-9.
13. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
14. Breeman WA, Kwekkeboom DJ, Kooij PP, Bakker WH, Hofland LJ, Visser TJ et al. Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. J Nucl Med 1995; 36:623-7.
15. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46 Suppl 1:92S-8S.
16. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22.
17. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-71.
18. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2005;32:1288-95.
19. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-22.
20. 111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28:1319-25.
21. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003;30:917-20.
22. Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med 2000;41:149-60.
23. Konijnenberg MW, Bijster M, Krenning EP, De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J Nucl Med 2004;45:1260-9.
24. Zidan M, Pabst R. Lymphocyte proliferation in lymphoid organs of the dromedary camel using the monoclonal antibody MIB-5 against the proliferation-associated nuclear epitope Ki-67. Anat Histol Embryol 2002;31:286-9.
25. 3-octreotate on tumor volume, cell density, activity concentration, and uptake of subsequent injection in tumor-bearing nude mice. Annual Meeting Society of Nuclear Medicine 2006 (abstract no. 1583).
26. Béhé M, Püsken M, Henzel M, Gross M, Reitz I, Engelhart-Cabillic E et al. Upregulation of gastrin and somatostatin receptor after irradiation. Eur J Nucl Med Mol Imaging 2003;30:S218.
27. Béhé M, Koller S, Püsken M, Gross M, Alfke H, Keil B et al. Irradiation-induced upregulation of somatostatin and gastrin receptors in vitro and in vivo. Eur J Nucl Med Mol Imaging 2004;31:S237-8.
28. Kim YJ, Ketter R, Henn W, Zang KD, Steudel WI, Feiden W. Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch 2006;449:529-38.
29. Aaltomaa S, Karja V, Lipponen P, Isotalo T, Kankkunen JP, Talja M et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 2006;26:4873-8.
30. Lundin J, Nordling S, von Boguslawsky K, Roberts PJ, Haglund C. Prognostic value of Ki-67 expression, ploidy and S-phase fraction in patients with pancreatic cancer. Anticancer Res 1995;15:2659-68.
31. Railo M, Lundin J, Haglund C, von Smitten K, Nordling S. Ki-67, p53, ER receptors, ploidy and S phase as long-term prognostic factors in T1 node-negative breast cancer. Tumour Biol 2007;28:45-51.
32. 90Y-DOTATOC. J Nucl Med 2005; 46:1310-6.